4.105USD-2.49%Mkt Cap: 165.82M USDP/E: —Last update: 2026-05-26
OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead pr…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap165.82M USD
Enterprise Value-27.29M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-59.52M USD
Revenue/Share—
Last Price4.105 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees45
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.91
PEG—
EV/EBITDA0.45
EV/Revenue—
P/S—
P/B0.89
EPS (TTM)-4.32
EPS (Forward)-2.13
52W Range
1.91063% of range5.380
52W High5.380 USD
52W Low1.910 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-105.93%
ROA-95.81%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-51.83M USD
CapEx (TTM)46.00K USD
FCF Margin—
FCF Yield-14.60%
Net Debt-191.70M USD
Net Debt/EBITDA3.14
Balance Sheet
Debt/Equity0.01
Current Ratio13.78
Quick Ratio13.41
Book Value/Sh4.564 USD
Cash/Share4.756 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:10
Split DateOct 7, 2024
Analyst Consensus
Rating1.3 (Strong Buy)
Target (Mean)20.20 USD
Target Range11.00 USD – 30.00 USD
# Analysts5
Ownership
Shares Out.40.40M
Float19.64M
Insiders10.48%
Institutions74.91%
Short Interest
Short Ratio0.6d
Short % Float0.29%
Short % Out.0.25%
Shares Short103.37K
Short (prev mo.)163.90K
Technical
SMA 504.223 (-2.8%)
SMA 2003.171 (+29.4%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)156.81K
Avg Vol (10d)190.07K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—